Aristopharma Ltd. has launched Rituris 100 & 500 mg concentrated solution for IV infusion, which is a preparation of Rituximab
Rituris (Rituximab) is a human monoclonal antibody that binds specifically to the transmembrane antigen CD20. This antigen is located on pre-B and mature B lymphocytes, but not on hemopoietic stem cells, pro-B cells, normal plasma cells, or other normal tissue. Rituris binds to the CD20 antigen on B lymphocytes and initiates immunologic reactions that mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis.
FR
DE